Zhitong Financial APP News, Shuanglu Pharmaceutical (002038.SZ) issued an announcement that the company's stock closed with a cumulative deviation of more than 20% for three consecutive trading days on October 12, October 13, and October 16, 2023, according to the relevant regulations of the Shenzhen Stock Exchange, which belongs to the situation of abnormal stock trading.
The company said that the company's research project GLP-1 receptor agonist (daily preparation) has completed three phases of follow-up of all participants and is in the stage of clinical data collation. The preliminary results show that the efficacy of the company's developed product is basically the same as that of the original drug Novoli, but there is no difference in safety. The weight loss clinical study of this product was not carried out alone, but the changes of body weight at baseline and 24 weeks after 24 weeks were observed as secondary indicators in the Ⅲ phase clinical study.
The company's research project, GLP-1-Fc fusion protein (Zhou preparation), is currently in the clinical phase of Ⅲ, and it is expected that all subjects will be enrolled in November and follow-up work will be completed in the first half of next year. The main curative effect index of this project is the change of glycosylated hemoglobin level, and the change of body weight is the secondary curative effect observation index.
Diapin, a patented variety jointly developed by the company and the University of Michigan in the United States, is currently in the preclinical stage. Diapin is a tripeptide analogue, and Shuanglu Pharmaceutical has the exclusive right to develop and use this compound in the Chinese market. In vitro and animal experiments, it has been shown that Diapin can effectively promote the secretion of GLPs-1 and insulin, thus reduce blood glucose, regulate intestinal flora, improve metabolism and treat nonalcoholic fatty liver (NASH). It can effectively inhibit the progression of NASH in non-human primates. The advantage of this product is oral administration. The NASH study was jointly carried out by researchers from the University of Michigan in the United States, Xi'an Jiaotong University in China and Peking University. The results were published in CellMetabolism in April 2023. Therefore, the company intends to increase the indications of the product and then apply for clinical application, which is currently in the preclinical stage.
The company's research project involving GLP-1 dual-target therapeutic drugs is still in the stage of preclinical research.